Clinical trial • Phase III • Cardiology
COR-1167 for Chronic heart failure
Phase III trial of COR-1167 for Chronic heart failure. Randomised. 20 participants.
Overview
- Trial Therapeutic Area
- Cardiology
- Trial Disease
- Chronic heart failure
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 27-03-2026
- First CTIS Authorization Date
- 13-05-2026
Trial design
Randomised Phase III trial across 1 site in Netherlands.
- Randomised
- Yes
- Target Sample Size
- 20
Recruitment
- Planned Sample Size
- 20
- Recruitment Window Months
- 4
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 20
Netherlands
- Earliest CTIS Part Ii Submission Date
- 05-05-2026
- Latest Decision Or Authorization Date
- 13-05-2026
- Processing Time Days
- 8
- Number Of Sites
- 1
- Number Of Participants
- 20
Sites
- Site Name
- Pharmaceutical Research Associates Group B.V.
- Department Name
- Program Management
- Contact Person Name
- Maria Velinova-Donga
- Contact Person Email
- Maria.Velinova@iconplc.com
Sponsor
Primary sponsor
- Full Name
- Corteria Pharmaceuticals
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- France
Contract research organisations
- Name
- Pharmaceutical Research Associates Group B.V.
Investigational products
- Investigational Product Name
- COR-1167
- Routes Of Administration
- Subcutaneous
- Route
- Subcutaneous
Related trials
Other published trials that may interest you.